TAM
JNCE

Tocqueville Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Tocqueville Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-21,450
Closed -$164K – 855
2018
Q2 		$164K Sell
21,450
-21,500
-50% -$310K ﹤0.01% 794
2018
Q1 		$960K Hold
42,950
– – 0.01% 515
2017
Q4 		$548K Buy
+42,950
New +$631K 0.01% 596

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tocqueville Asset Management's JNCE Position: Q3 2018 in Review

Tocqueville Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2018, closing a stake of 21,450 shares — an estimated $164K sold.

Tocqueville Asset Management first reported a position in JNCE in Q4 2017 and held it in 3 quarters. The position peaked at $960K in Q1 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q3 2018.

  • Tocqueville Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Tocqueville Asset Management sold 21,450 Jounce Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $164K.
  • Tocqueville Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 3 quarters.
  • Tocqueville Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $960K in Q1 2018.
  • 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Tocqueville Asset Management's 13F filing for Q3 2018, filed 13 Nov 2018.